Bayer has announced that it will voluntarily withdraw its follicular lymphoma drug Aliqopa, also known as copanlisib, from the U.S. market. The decision comes after a clinical trial failed to demonstrate the desired effect on overall survival, leading to discussions with the U.S. Food and Drug Administration (FDA).
Aliqopa was initially granted accelerated approval by the FDA in 2017 based on Phase II study results. The drug was intended for use in adults with follicular lymphoma who had experienced a relapse after at least two prior systemic therapies. However, this approval was contingent upon further trials to confirm its benefits.
In a follow-up study as required by the FDA, adding Aliqopa to standard immunochemotherapy did not meet the targeted progression-free survival when compared to the control group of patients receiving standard immunochemotherapy alone. As a result, Bayer made the decision to withdraw the drug from the U.S. market.
Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma that affects the body's white blood cells. Aliqopa was developed as a targeted treatment option, specifically inhibiting PI3K-delta, a protein involved in tumor cell growth. The drug's accelerated approval was a promising step towards addressing the needs of patients with relapsed follicular lymphoma.
While Aliqopa showed potential in early clinical trials, the recent trial's results were not favorable in terms of overall survival. Bayer's decision to withdraw the drug is a responsible move, prioritizing patient safety and ensuring that only those treatments that demonstrate significant benefits are made available in the market.
Bayer has stated that it will work closely with the FDA to ensure a smooth withdrawal of Aliqopa from the market. The company remains committed to continuing its research and development efforts to address unmet medical needs, including evaluating new therapeutic options for patients with follicular lymphoma. This setback underscores the challenges faced in developing effective treatments for complex diseases like cancer.
Patients currently receiving Aliqopa are advised to consult their healthcare providers for appropriate alternative treatment options. It is crucial for patients to have access to effective therapies and for pharmaceutical companies to continue their research and development efforts to bring new and improved treatments to the market.